Abstract
Selenium (Se), an essential trace element, has also been identified as an anticarcinogenic agent, with supporting evidence from epidemiological studies, clinical intervention trials, preclinical intervention studies (animal cancer models) and cell culture studies. Natural organic and inorganic sources of Se as well as synthetic organoselenium compounds have been shown to be effective; safety and efficacy factors favour the organic forms. Intakes that are several fold that purported to meet nutritional requirements (adult recommend dietary allowance - 55 μg Se/day) are associated with reductions in cancer risk, but are not currently met by most diets, unless Se-rich foods are included. Further clinical studies and development of tools for speciating Se in foods will enable progress to be made in determining desirable Se forms and foods with respect to providing safe and effective ways of reducing cancer risk.
Keywords: Chemoprevention, colorectal cancer, health benefit, selenium, selenium-rich foods, anticarcinogenic agent, synthetic organoselenium compounds, efficacy factors, selenoproteins, Se-rich soil, organoselenium compounds
Current Pharmaceutical Biotechnology
Title: Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Volume: 13 Issue: 1
Author(s): Ying Hu, Graeme H. McIntosh and Graeme P. Young
Affiliation:
Keywords: Chemoprevention, colorectal cancer, health benefit, selenium, selenium-rich foods, anticarcinogenic agent, synthetic organoselenium compounds, efficacy factors, selenoproteins, Se-rich soil, organoselenium compounds
Abstract: Selenium (Se), an essential trace element, has also been identified as an anticarcinogenic agent, with supporting evidence from epidemiological studies, clinical intervention trials, preclinical intervention studies (animal cancer models) and cell culture studies. Natural organic and inorganic sources of Se as well as synthetic organoselenium compounds have been shown to be effective; safety and efficacy factors favour the organic forms. Intakes that are several fold that purported to meet nutritional requirements (adult recommend dietary allowance - 55 μg Se/day) are associated with reductions in cancer risk, but are not currently met by most diets, unless Se-rich foods are included. Further clinical studies and development of tools for speciating Se in foods will enable progress to be made in determining desirable Se forms and foods with respect to providing safe and effective ways of reducing cancer risk.
Export Options
About this article
Cite this article as:
Hu Ying, H. McIntosh Graeme and P. Young Graeme, Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention, Current Pharmaceutical Biotechnology 2012; 13 (1) . https://dx.doi.org/10.2174/138920112798868809
DOI https://dx.doi.org/10.2174/138920112798868809 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy K-Ras, Intestinal Homeostasis and Colon Cancer
Current Clinical Pharmacology Meet Our Editor:
Recent Patents and Topics on Imaging (Discontinued) Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Molecular Chaperone Activity and Biological Regulatory Actions of the TPR-Domain Immunophilins FKBP51 and FKBP52
Current Protein & Peptide Science From Presenilinase to γ-Secretase, Cleave to Capacitate
Current Alzheimer Research Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Therapeutic Proteins: A to Z
Protein & Peptide Letters Recent Advances on Small-Molecule Survivin Inhibitors
Current Medicinal Chemistry Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Meet our Editor (Genetics)
Current Chinese Science Affinity-Based Methods in Drug-Target Discovery
Current Drug Targets Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents Nitric Oxide-Releasing Non Steroidal Anti-Inflammatory Drugs: A New Generation of Anti-Tumoral Molecules
Current Cancer Drug Targets Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma
Current Pharmaceutical Design Nucleoprotein-Derived and Unbound Ribonucleosides: Bioactivity and Potential Applications
Current Pharmaceutical Design